Jasper Therapeuti…
USUSDJasper Therapeutics, Inc. (US:JSPR) — Biotechnology: Biological Products (No Diagnostic Substances). Börside arv, kus ettevõtte aktsiatega kaubeldakse: 1. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- jaspertx.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Peakontor
- REDWOOD CITY, United States
- Ringluses Olevad Aktsiad
- 33.27 mln seisuga 2026-08-10
- Turukapitalisatsioon
- 20.83 mln USD
- Siseringi Isikud
- 2.87%
- Institutsionaalsed Investorid
- 39.43%
- Tegevusala (SIC)
- Biological Products, (No Diagnostic Substances)
- FCF
- −60.3 mln USD
- Võlg
- 400 tuh USDnetoraha
- Kasum ja FCF — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
Kirjeldus
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
Börsid ja Tikkerid
| Börs | Tikker | Valuuta | Hind | Tüüp |
|---|---|---|---|---|
| US USA Stocks | JSPR | USD | 0.5702 +1.82% | tavalised aktsiad |
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| Velan Capital Investment… | 16.04% | 5.34 mln | 2026-06-30 |
| Acorn Capital Advisors,… | 8.64% | 2.88 mln | 2026-06-30 |
| Kingdon Capital Manageme… | 8.13% | 2.7 mln | 2026-06-30 |
| Vanguard Capital Managem… | 7.04% | 2.34 mln | 2026-06-30 |
| Rock Springs Capital Man… | 6.62% | 2.2 mln | 2026-06-30 |
| Carlyle Group Inc. | 6.41% | 2.13 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 5.01% | 1.67 mln | 2026-06-30 |
| GSA Capital Partners LLP | 3.21% | 1.07 mln | 2026-06-30 |
| Millennium Management Ll… | 2.93% | 973 866 | 2026-06-30 |
| Lion Point Capital, LP | 2.79% | 930 000 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.88% | 624 064 | 2026-06-30 |
| Geode Capital Management… | 1.59% | 527 616 | 2026-06-30 |
| SHIZURU JUDITH ANNE M.D.… | ≈0.47% | 156 901 | 2025-09-22 |
| Fidelity Concord Street… | 0.38% | 127 525 | 2026-07-31 |
| MARTELL RONALD A (Chief… | ≈0.22% | 74 118 | 2025-09-22 |
| VANGUARD VALLEY FORGE FU… | 0.16% | 53 196 | 2026-06-30 |
| Fidelity Concord Street… | 0.15% | 49 896 | 2026-07-31 |
| Fidelity Concord Street… | 0.1% | 34 109 | 2026-07-31 |
| MAHAL JEETINDER SINGH (C… | ≈0.08% | 25 009 | 2024-12-12 |
| LUCAS SVETLANA (Director… | ≈0.06% | 20 000 | 2025-09-22 |
| ADVISORS' INNER CIRCLE I… | 0% | 292 | 2026-04-30 |
| WIGGANS THOMAS G (Direct… | — | — | 2025-09-22 |
Logi Sisse Google